外周血CD4+T细胞计数对免疫性血小板减少症患者药物治疗效果评估作用分析

Abstract
Figure/Table
References (25)
Related Citation (14)

Download: PDF (619 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To analyze the effect of peripheral blood CD4+ T cell count on the evaluation of drug treatment effect in patients with immune thrombocytopenia (ITP). Methods A total of 80 ITP patients admitted to Huangshan People’s Hospital, Anhui Province (hereinafter referred to as “our hospital”) from January 2018 to December 2020 who received glucocorticoid treatment after admission were selected as the study group, and 30 healthy volunteers who underwent physical examination in our hospital during the same period were selected as the control group. Difference in peripheral blood CD4+T cell count before the treatment of stndy group were compared between the two groups. The changes of peripheral blood CD4+T cell count before and after treatment were compared in the study group. The study group was divided into the effective group (62 cases) and the ineffective group (18 cases) according to the treatment effect. The disease-related indicators of the effective group and the ineffective group were compared, and the factors influencing the treatment effect were analyzed, as well as the predictive value of peripheral blood CD4+T cell count on the treatment effect. Results Before the treatment of study group, the peripheral blood CD4+T cell count of the study group was lower than that of the control group, the difference was statistically significant (P ＜ 0.05). After treatment, the peripheral blood CD4+T cell count of the study group was higher than that before treatment, the difference was statistically significant (P ＜ 0.05). The megakaryocytes count and peripheral blood CD4+T cell count of effective group were higher than those of ineffective group, and the differences were statistically significant (P ＜ 0.05). Multivariate analysis showed that megakaryocyte count and peripheral blood CD4+T cell count were the influencing factors of drug treatment effect in ITP patients (P ＜ 0.05). The area under the receiver operating characteristic curve of peripheral blood CD4+T cell count on drug treatment effect of ITP patients was 0.765 (P ＜ 0.05). Conclusion Abnormal expression of peripheral blood CD4+T cell count in ITP patients is a factor affecting the efficacy of drug treatment in ITP patients, and has certain predictive value for the efficacy of drug trextment in ITP patients.

Key words： CD4+ T cell count Peripheral blood Immune thrombocytopenia

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WANG Qiong WANG Yong WU Yuling▲

Cite this article:

WANG Qiong WANG Yong WU Yuling▲. Analysis of the effect of peripheral blood CD4+ T cell count on the evaluation of drug treatment effect in patients with immune thrombocytopenia[J]. 中国医药导报, 2022, 19(23): 121-124.

URL:

https://www.yiyaodaobao.com.cn/EN/ OR https://www.yiyaodaobao.com.cn/EN/Y2022/V19/I23/121

[1] Terrell DR，Beebe LA，Vesely SK，et al. The incidence of immune thrombocytopenic purpura in children and adults：A critical review of published reports [J]. Am J Hematol，2010，85（3）：174-180.
[2] 李炀，孙丽华，李锋，等.重组人血小板生成素在老年重症免疫性血小板减少症患者一线治疗中的短期疗效分析[J].中国临床医学，2021，28（3）：370-374.
[3] 王宗平.糖皮质激素联合重组人白细胞介素-11在原发免疫性血小板减少症中的应用[J].中国药物与临床，2020， 20（6）：923-924.
[4] 杨翠，韩效林，字友梅，等.小牛脾提取物注射液联合糖皮质激素对原发免疫性血小板减少症患者免疫功能的影响[J].新乡医学院学报，2020，37（2）：136-139.
[5] 林晓静，邹兴立，赵小蓉，等.重组人促血小板生成素与丙种球蛋白联合糖皮质激素治疗重症ITP的疗效比较[J].川北医学院学报，2021，36（2）：159-162.
[6] 于慧辉，詹延霞，季丽莉，等.原发性免疫性血小板减少症（ITP）患者CD5+B细胞对CD4+T细胞Th1/Th2型细胞因子分泌的影响[J].复旦学报（医学版），2020，12（1）：53-58.
[7] 中华医学会血液学分会止血与血栓学组.成人原发免疫性血小板减少症诊断与治疗中国指南专家共识（2016年版）[J].中华血液学杂志，2016，37（2）：89-93.
[8] 潘旭旭，王弘.长春地辛治疗原发性免疫性血小板减少症临床有效性分析[J].实用药物与临床，2020，23（3）：217-220.
[9] 陶红，何正梅，史玉叶，等.重组人血小板生成素治疗老年免疫性血小板减少症的疗效与安全性分析及对Th1/Th2相关细胞因子的调控作用研究[J].中国医药科学，2021，11（2）：22-24，29.
[10] 余文俊，林建雄，张泽文.慢性原发免疫性血小板减少症患者血小板microRNA差异表达的研究[J].中国医药科学，2020，10（10）：7-10.
[11] 陈哲，郭成山.自身免疫耐受失调及其在免疫性血小板减少症发病机制中的研究进展[J].国际免疫学杂志，2020，43（2）：196-200.
[12] 陈哲，张灵，刘洁，等.原发免疫性血小板减少症患者外周血CD4+T淋巴细胞表面PD-1表达水平分析[J].中国医药导报，2021，18（1）：92-95.
[13] 李傲航，田媛媛，张金仿.原发免疫性血小板减少症患者血清细胞因子水平变化与血小板参数的相关性研究[J].临床和实验医学杂志，2021，20（15）：1679-1680.
[14] 陈滔，高建龙.rhTPO联合小剂量激素治疗原发性免疫性血小板减少症的疗效研究[J].中国妇幼保健，2020， 35（7）：1246-1248.
[15] Vrbensky JR，Nazy I，Clare R，et al. T cell-mediated autoimmunity in immune thrombocytopenia [J]. Eur J Haematol，2022，108（1）：18-27.
[16] 张雷，何流，杨敏，等.CD80，CD86表达水平与免疫性血小板减少症患者免疫功能相关性[J].热带医学杂志，2020，20（2）：241-244.
[17] 李培岭，王欣欣，范蕊，等.T淋巴细胞相关细胞因子与儿童慢性免疫性血小板减少症转归的相关性研究[J].中华实用儿科临床杂志，2020，35（3）：206-209.
[18] 闫彦睿，王志银，李培岭，等.调节性T细胞和淋巴细胞亚群在儿童免疫性血小板减少症发病中的意义[J].新乡医学院学报，2021，38（2）：129-132.
[19] 周莉，张馨慧，何柳婷，等.T细胞组套检测对原发性免疫性血小板减少症病情预判及治疗药物选择的指导应用[J].中国临床研究，2021，34（9）：1194-1198.
[20] 王彬，邵宽芙蓉，董晨.CD4+T淋巴细胞亚群在过敏性紫癜发病机制中的研究进展[J].医学综述，2020，26（15）：2940-2944.
[21] 陈洋，闫薛，张婷，等.激素无效型免疫性血小板减少症患者T淋巴细胞亚群与血小板特异性自身抗体的相关性分析[J].临床血液学杂志，2021，34（11）：807-810.
[22] 罗洪强，封蔚莹，周国忠.重组人血小板生成素对难治性原发性免疫性血小板减少性紫癜患者T、B淋巴细胞功能的影响[J].中国卫生检验杂志，2019，29（17）：2089-2091.
[23] 张晴，高长俊.原发免疫性血小板减少症患儿中T淋巴细胞亚群、NK细胞及B细胞在外周血中的表达情况分析[J].实用临床医药杂志，2017，21（17）：45-47.
[24] 沈伟，何林波，唐灵通.原发免疫性血小板减少症患者外周血CD4+T淋巴细胞与IL-37表达的变化及意义[J].解放军预防医学杂志，2018，36（4）：500-502.
[25] 郭晓，邢玉敏，李文静，等.健脾止血汤联合短程大剂量地塞米松对慢性原发免疫性血小板减少症治疗的临床研究[J].河北中医药学报，2020，35（5）：27-30.